Get the Stockscreener App
4.36
7.23%
-0.34
After Hours:
4.38
0.02
+0.46%
BiomX Inc stock is traded at $4.36, with a volume of 55,891.
It is down -7.23% in the last 24 hours and down -60.27% over the past month.
BiomX Inc., a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targets bacteria associated with progressive liver disorder (PSC), a rare inflammatory liver disease; and CRC, targets strains of bacteria found in colorectal cancer tumors. The company has license agreement collaboration with The Weizmann Institute of Science to develop, test, manufacture, produce, and sell microbiome-based therapeutic product candidate; Takeda, develops formulations for phage therapy manufacturing intermediates and for the final form to be administered; Keio University and JSR Corporation, a set of bacterial targets for the development and commercialization of phage therapies to treat IBD; and Janssen Research & Development, LLC to utilize XMarker microbiome-based biomarker discovery platform. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
See More
Previous Close:
$4.70
Open:
$4.63
24h Volume:
55,891
Relative Volume:
1.26
Market Cap:
$7.18M
Revenue:
-
Net Income/Loss:
$-23.14M
P/E Ratio:
-4.3036
EPS:
-1.0131
Net Cash Flow:
$-29.23M
1W Performance:
-10.01%
1M Performance:
-60.27%
6M Performance:
-54.11%
1Y Performance:
-61.83%
1-Day Range:
$4.10
$4.6384
1-Week Range:
$4.10
$5.95
52-Week Range:
$4.10
$22.06
BiomX Inc Stock (PHGE) Company Profile
Name
BiomX Inc
Sector
Industry
Phone
972 7 23942377
Address
7 Pinhas Sapir Street, 2nd Floor, Ness Ziona
Compare PHGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHGE
BiomX Inc
|
4.36 | 7.18M | 0 | -23.14M | -29.23M | -1.0131 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
BiomX Inc Stock (PHGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-21 | Initiated | Ladenburg Thalmann | Buy |
BiomX Inc Stock (PHGE) Latest News
H.C. Wainwright reiterates Buy rating on BiomX stock amid FDA queries By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy rating on BiomX stock amid FDA queries - Investing.com Canada
BiomX (NYSEAMERICAN:PHGE) Stock Price Expected to Rise, HC Wainwright Analyst Says - Defense World
HC Wainwright Issues Optimistic Estimate for BiomX Earnings - Defense World
BiomX (NYSEAMERICAN:PHGE) Price Target Raised to $26.00 at HC Wainwright - Defense World
HC Wainwright Issues Positive Forecast for BiomX (NYSEAMERICAN:PHGE) Stock Price - Defense World
HC Wainwright Boosts BiomX (NYSEAMERICAN:PHGE) Price Target to $26.00 - Defense World
HC Wainwright & Co. Reiterates BiomX (PHGE) Buy Recommendation - Nasdaq
Why Is BiomX Stock Falling Today?BiomX (AMEX:PHGE) - Benzinga
BiomX Awaits FDA Clearance To Restart Cystic Fibrosis Trial After Nebulizer Device Review - Sahm
PHGE: HC Wainwright & Co. Reiterates Buy Rating with $26 PT | PH - GuruFocus
BiomX To Continue Cystic Fibrosis Study With Revised Dosing Of BX004; Data Expected In Q2, 2026 - Nasdaq
BiomX Says Working to Lift FDA Hold Concerning Nebulizer Device in Phase 2b Study of BX004 for Cystic Fibrosis - MarketScreener
FDA Review Delays BiomX's (PHGE) Cystic Fibrosis Trial Progress - GuruFocus
BiomX Updates on Phase 2b Study for BX004 - TipRanks
BiomX provides update on BX004 Phase 2b trial in Cystic Fibrosis - TipRanks
BiomX Updates on FDA Clinical Hold and Study Progress - TradingView
BiomX (NYSE American: PHGE) DMC Backs BX004 Phase 2b Study, Topline Expected 2026 - Stock Titan
PHGE: HC Wainwright Raises Price Target for BiomX to $26.00 | PH - GuruFocus
HC Wainwright & Co. Maintains BiomX (PHGE) Buy Recommendation - Nasdaq
BiomX price target adjusted to $26 from $15 at H.C. Wainwright - TipRanks
Stock splits calendar for: - Yahoo Finance Singapore
BiomX announces FDA feedback on development pathway for BX011 - MSN
BiomX Inc. Reports Q3 2025 Financial Results and Program Updates - MSN
BiomX Inc. Earnings Call: Progress Amid Challenges - MSN
Why BiomX Inc. stock stays undervaluedJuly 2025 Trends & Precise Swing Trade Entry Alerts - newser.com
BiomX Stock to Reverse Split on Tuesday, November 25th (NYSEAMERICAN:PHGE) - Defense World
BiomX Stock to Reverse Split on Tuesday, November 25th (NYSEMKT:PHGE) - Defense World
BiomX Inc. COmmon Stock (NYSE:PHGE) Stock Quote - Markets Financial Content
Can BiomX Inc. stock retain market dominanceEarnings Recap Summary & Low Volatility Stock Recommendations - newser.com
Why BiomX Inc. stock could see breakout soonIndex Update & Proven Capital Preservation Methods - newser.com
Will BiomX Inc. stock see PE expansionJuly 2025 EndofMonth & Fast Entry High Yield Stock Tips - newser.com
Will BiomX Inc. stock extend growth storyPortfolio Profit Report & Real-Time Volume Trigger Notifications - newser.com
Is BiomX Inc. stock a momentum leader2025 Buyback Activity & Daily Profit Focused Screening - newser.com
BiomX Inc. (PHGE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Will BiomX Inc. stock attract long term capital inflowsFed Meeting & Safe Capital Investment Plans - newser.com
Will BiomX Inc. stock rise with strong economyJuly 2025 Highlights & Low Risk Entry Point Tips - newser.com
Forecasting BiomX Inc. price range with options dataJobs Report & AI Forecast Swing Trade Picks - newser.com
BiomX Inc Stock (PHGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):